Jan 2011: Adjunct Professor Griffith Uni.Mar 2008: Became Chairman Pharmasynth, biological CMO focused on chemical scale up/manufacturing services May 2007-Sept 2008: V P Manufacturing Progen – responsible for all manufacturing operations including PI-88, Progens oncology drug for liver cancer as well as other products such as cytotoxics 11047/11093 and PG545. Still active CMC consultant to ProgenJan 2005: Joined Board of Research Directions, CMO focused on providing scale up/development services. In 2010 negotiated contract for manufacture of large vet productNov 2004: Joined Board of MigCo-focused on development of API’s for prevention/treatment of Migraine.Mar 2004: Joined Board of Chirogen-Dec 1999-June 2003: VP R+D, Organichem Corp, Rensselaer New York 12144I was one of the founders of Organichem, the result of an MBO. It is a contract manufacturer of API’s and advanced intermediates. It supplies contrast media for a variety of diagnostic imaging techniques like X-ray, MRI, ultrasound. It also has a thriving contract business targeted around core strengths of GMP compliance, high potency/controlled substance manufacturing. From 1999 to 2003 Organichem grew sales from US $42M to US$85M (EBIT from US$3.6M to US$14.2M). It was sold in 2003.Jul 1997-Dec 1999: Director R and D Nycomed Amersham, Rensselaer Jul 1994-Jul 1997: Development/QC Lab Manager QCI, 1515 Nicolas Rd Dayton, Ohio 45418cGMP manufacturer. I also managed the QC lab at QCiJuly 1991-July 1994: Senior Chemist, FCC Pascagoula, Mississippi,FCC is a commodity chemical producer specializing in nitration/reduction/esterification technology. At FCC I was responsible for operation of their high pressure lab. Feb 1990-Jul 1991: Research Manager FCC Program at MSU Starkville, Mississippi. 39715FCC had an active R+D program at MSU to screen many potentially new projects /carry out preliminary optimization.